Add Yahoo as a preferred source to see more of our stories on Google. In an early clinical trial, a single dose of a short-acting psychedelic drug led to rapid improvement in people with major ...

A powerful psychedelic, best known for its intense but brief effects, may offer a new way to treat depression. In a Phase 2 clinical trial at Imperial College London, a single intravenous dose of ...

The Phase 2 study will assess a sub-psychedelic dose of DMT in patients who have suffered an acute ischemic stroke. The biotech is advancing clinical research on DMT for stroke treatment and its ...

A recent study published in Nature Medicine suggests that a brief psychedelic experience combined with talk therapy can ...

Algernon Pharmaceuticals’ AGNPF wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) ...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of ...

VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ...

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ...

From the dark annals of Erowid forums to Joe Rogan’s podcast studio, there’s perhaps no psychoactive drug more enigmatic — and misunderstood — than N,N-Dimethyltryptamine, better known as DMT. The ...